Carvedilol prevents and reverses hypertrophy-induced cardiac dysfunction

Pharmacology

Volumn 80, Issue 2-3, 2007, Pages 166-176

  Barone, Frank C ^a,d   Willette, Robert N ^b   Nelson, Allen H ^b   Ohlstein, Eliot H ^b   Brooks, David P ^b   Coatney, Robert W ^c  

^a High Throughput Biology   (United States)

^b Centres of Excellence for Cardiovascular Urogenital Drug Discovery   (United States)

^c GLAXOSMITHKLINE   (United States)

^d NONE   (United States)

Author keywords

Cardiac hypertrophy; Cardiac output; Cardiac ventricular mass; Cardiomyopathy; Carvedilol; Ejection fraction; End organ protection; Heart failure; Hypertension; Left ventricular chamber diameter; Left ventricular wall thickness; Stroke volume

Indexed keywords

CARVEDILOL; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIETARY INTAKE; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; ELECTROCARDIOGRAM; FEEDING; HEART DISEASE; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART OUTPUT; HEART PROTECTION; HEART STROKE VOLUME; HEART VENTRICLE HYPERTROPHY; LIPID DIET; LONGEVITY; MALE; MEDICAL RESEARCH; NONHUMAN; ORGAN INJURY; PRIORITY JOURNAL; RAT; WISTAR KYOTO RAT;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIOXIDANTS; CARBAZOLES; CARDIOMEGALY; DIET; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; PROPANOLAMINES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; TREATMENT OUTCOME; VASODILATOR AGENTS; VENTRICULAR REMODELING;

EID: 34547818765     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000103384     Document Type: Article

References (65)

1. Feuerstein GZ, Poste G, Ruffolo RR: Carvedilol update III: rationale for use in congestive heart failure. Drugs Today 1995;31:307-326.
2. Ruffolo RR Jr, Gellai M, Hieble JP, Willette RN, Nichols AJ: The pharmacology of carvedilol. Eur J Clin Pharmacol 1990; 38(suppl):82-88.
3. Ruffolo RR Jr, Boyle DA, Venuti RP, Lucas MA: Carvedilol (Kredex): a novel, multiple action cardiovascular agent. Drugs Today 1991;27:465-492.
4. Cleland JG: Progression from hypertension to heart failure. Mechanisms and management. Cardiology 1999;92(suppl 1):10-19; discussion pp 20-21.
5. Stroe AF, Gheorghiade M: Carvedilol: beta-blockade and beyond. Rev Cardiovasc Med 2004;5(suppl 1):S18-S27.
6. Sharpe N: Cardiac remodeling in coronary artery disease. Am J Cardiol 2004;93:17B-20B.
7. Di Lenarda A, Sabbadini G, Salvatore L, Sinagra G, Mestroni L, Pinamonti B, Gregori D, Ciani F, Muzzi A, Klugmann S, Camerini F: Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group. J Am Coll Cardiol 1999;33:1926-1934.
8. Barone FC, Nelson AH, Ohlstein EH, Willette RN, Seally JE, Laragh JH, Campbell WG Jr, Feuerstein GZ: Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats. J Pharmacol Exp Ther 1996;279:948-955.
9. Ma XL, Yue T-L, Lopez BL, Barone FC, Christopher TA, Ruffolo RR, Feuerstein GZ: Carvedilol, a new beta adrenoceptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits. J Pharmacol Exp Ther 1996;277:128-136.
10. Yue T-L, Cheng HY, Lysko PG, McKenna PJ, Feuerstein R, Gu JL, Lysko KA, Davis LL, Feuerstein GZ: Carvedilol, a new vasodilator and beta-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 1992;263:92-98.
11. Yue T-L, Feuerstein GZ: Carvedilol, a new vasodilator and β-adrenoceptor antagonist, inhibits oxygen-radical-mediated lipid peroxidation in swine ventricular membranes. Pharmacol Commun 1992;1:27-35.
12. Yue T-L, Lysko PG, Barone FC, Ruffolo RR, Feuerstein GZ: Carvedilol, a new antihypertensive drug with unique antioxidant activity; potential role in cerebroprotection. NY Acad Sci 1995;738:230-242.
13. Yue T-L, McKenna PJ, Cheng HY: Carvedilol, a new antihypertensive agent, prevents oxidative injury to endothelial cells. Hypertension 1993;22:922-928.
14. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N: Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-2816.
15. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA: Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800-2806.
16. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Larrabee P, Bristow MR: Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94:2817-2825.
17. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, Levin HR, Neuberg GW, DeLong G, Packer M: Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe heart failure. Circulation 1995;92:1499-1506.
18. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR: Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 1995;25:1225-1231.
19. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355.
20. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH: Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996;94:2793-2799.
21. Palazzuoli A, Quatrini I, Vecchiato L, Scali C, De Paola V, Iovine F, Martini G, Nuti R: Effects of carvedilol on left ventricular diastolic function and chamber volumes in advanced heart failure. Minerva Cardioangiol 2005;53:321-328.
22. Filipiak KJ, Opolski G: Beta-adrenolytics in heart failure - are they all really equal (in Polish)? Przegl Lek 2005;62(suppl 2):39-42.
23. Castro P, Perez O, Greig D, Diaz-Araya G, Moraga F, Chiong M, Troncoso R, Padilla I, Vukasovic JL, Corbalan R, Lavandero S: Effects of carvedilol on functional capacity, left ventricular function, catecholamines and oxidative stress in patients with chronic heart failure. Rev Esp Cardiol 2004;57:1053-1058.
24. Cice G, Tagliamonte E, Ferrara L, Iacono A: Efficacy of carvedilol on complex ventricular arrhythmias in dilated cardiomyopathy: double-blind, randomized, placebo-controlled study. Eur Heart J 2000;21:1259-1264.
25. Fujimura M, Yasumura Y, Ishida Y, Nakatani S, Komamura K, Yamagishi M, Miyatake K: Improvement in left ventricular function in response to carvedilol is accompanied by attenuation of neurohumoral activation in patients with dilated cardiomyopathy. J Card Fail 2000;6:3-10.
26. Bril A, Slivjak M, DiMartino MJ, Feuerstein GZ, Linee P, Poyser RH, Ruffolo RR Jr, Smith EF III: Cardioprotective effects of carvedilol, a novel β-adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: comparison with propranolol. Cardiovasc Res 1992;26:518-525.
27. Feuerstein GZ, Hamburger SA, Smith EF III, Bril A, Ruffolo RR Jr: Myocardial protection with carvedilol. J Cardiovasc Pharmacol 1992;19(suppl 1):S138-S141.
28. Hamburger SA, Barone FC, Feuerstein GZ, Ruffolo RR Jr: Carvedilol (Kredex) reduces infarct size in a canine model of acute myocardial infarction. Pharmacology 1991;43:113-120.
29. Singh D, Chander V, Chopra K: Carvedilol attenuates ischemia-reperfusion- induced oxidative renal injury in rats. Fundam Clin Pharmacol 2004;18:627-634.
30. Savitz SI, Erhardt JA, Anthony JV, Gupta G, Li X, Barone FC, Rosenbaum DM: The novel β-blocker, carvedilol, provides neuroprotection in transient focal stroke. J Cereb Blood Flow Metab 2000;20:1197-1204.
31. Brooks DP, Short BG, Cyronak MJ, Contino LC, DiCristo M, Wang Y-X, Ruffolo RR Jr: Comparison between carvedilol and captopril in rats with partial ablation-induced chronic renal failure. Br J Pharmacol 1993;109:581-586.
32. Wong VY, Laping NJ, Nelson AH, Contino LC, Olson BA, Gygielko E, Campbell WG Jr, Barone FC, Brooks DP: Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGFβ expression. Br J Pharmacol 2001;134:977-984.
33. Ma XL, Gao F, Nelson AH, Lopez BL, Christopher TA, Yue TL, Barone FC: Oxidative inactivation of nitric oxide and endothelial dysfunction in stroke-prone spontaneously hypertensive rats. J Pharmacol Exp Ther 2001;298:879-885.
34. Ohlstein EH, Vickery L, Arleth A, Cyronak M, Barone FC, Sung CP, Cadogen A, McCartney L: Carvedilol, a novel cardiovascular agent, inhibits development of vascular and ventricular hypertrophy in spontaneously hypertensive rats. Clin Exp Hypertens 1994;16:163-177.
35. Ohlstein EH, Douglas SA, Sung C-P, Yue T-L, Louden C, Arleth A, Poste G, Ruffolo RR Jr, Feuerstein GZ: Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci USA 1993;90:6189-6193.
36. Barone FC, Campbell WG Jr, Nelson AH, Feuerstein GZ: Carvedilol prevents severe hypertensive cardiomyopathy and remodeling. J Hypertens 1998;16:871-884.
37. Nagoaka A, Iwatsuka H, Sozuski Z, Okamoto K: Genetic predisposition to stroke in spontaneously hypertensive rats. Am J Physiol 1976;230:1354-1359.
38. Barone FC, Coatney RW, Chandra S, Sarkar SK, Nelson AH, Contino LC, Brooks DP, Campbell WG, Ohlstein EH, Willette RN: Eprosartan reduces cardiac hypertrophy, protects heart and kidney and prevents early mortality in severely hypertensive stroke-prone rats. Cardiovasc Res 2001;50:525-537.
39. Litwin SE, Katz SE, Weinberg EO, Lorell BH, Aurigenmma GP, Douglas PS: Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy. Chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure. Circulation 1995;91:2642-2654.
40. Haas GJ, McCune SA, Brown DM, Cody RJ: Echocardiographic characterization of left ventricular adaptation in a genetically determined heart failure rat model. Am Heart J 1995;130:806-811.
41. Okamoto K, Yamori Y, Nagaoka A: Establishment of the stroke-prone spontaneously hypertensive rat (SHR). Circ Res 1974;34-35(suppl 1):143-153.
42. Silverberg D, Wexler D, Blum M, Schwartz D, Iaina A: The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens 2004;13:163-170.
43. Frolich ED, Tarazi RC: Is arterial pressure the sole factor responsible for hypertensive cardiac hypertrophy? Am J Cardiol 1979;44:959-963.
44. Ganau A, Devereux RB, Pickering TG, Roman MJ, Schnall PL, Santucci S, Spitzer MC, Laragh JH: Relation of left ventricular load and contractile performance to left ventricular mass in hypertension. Circulation 1990;81:25-36.
45. De Simone G, Moccia D, Di Lorenzo L, Buonissimo S, Constantino G, de Divitiis O: Echocardiographic assessment of arterial impedance: relationship to anatomic left ventricular patterns in systemic hypertension. Am J Noninvasive Cardiol 1988;2:232-237.
46. Gordon AL, Inchiosa MA, Lehr D: Isoproterenol-induced cardiomegaly: assessment of myocardial protein content, actomysin ATPase and heart rate. J Mol Cell Cardiol 1972;4:543-557.
47. Sen S, Tarazi RC, Bumpus FM: Cardiac effects of angiotensin antagonists in normotensive rats. Clin Sci Lond 1979;56:439-443.
48. Friberg P, Ely DL, Wahlander H, Nilsson H, Folkow B: Cardiac design and pressure-volume characteristics of the left ventricle in normotensive (WKY) and hypertensive (SHR) rats after various dietary sodium treatments. Acta Physiol Scand 1986;126:477-484.
49. Lindpainter K, Sen S: Role of sodium in hypertensive cardiac hypertrophy. Circ Res 1985;57:610-617.
50. Sen S, Young DR: Role of sodium in modulation of myocardial hypertrophy in renal hypertensive rats. Hypertension 1998;8:918-924.
51. De Simone G, Devereux RB, Camargo MJF, Wallerson DC, Laragh JH: Influence of sodium intake on in vivo left ventricular anatomy in experimental renovascular hypertension. Am J Physiol 1993;33:H2103-H2110.
52. Udelson JE: Ventricular remodeling in heart failure and the effect of beta-blockade. Am J Cardiol 2004;93:43B-48B.
53. Kveiborg B, Christiansen B, Major-Petersen A, Torp-Pedersen C: Metabolic effects of beta-adrenoceptor antagonists with special emphasis on carvedilol. Am J Cardiovasc Drugs 2006;6:209-217.
54. Sitnikova MIu, Shliakhto EV: Endothelial protection in patients with apparent cardiac failure in long-term therapy by carvedilol. Klin Med (Mosk) 2003;81:44-47.
55. Chizzola PR, Goncalves de Freitas HF, Marinho NV, Mansur JA, Meneghetti JC, Bocchi EA: The effect of beta-adrenergic receptor antagonism in cardiac sympathetic neuronal remodeling in patients with heart failure. Int J Cardiol 2006;106:29-34.
56. Xue SR, Xue Y, Xue R: Carvedilol restores cardiac calcium release channel structure and function in heart failure. Int J Cardiol 2007;116:231-235.
57. Li X, Huang CX, Jiang H, Cao F, Wang T: The beta-adrenergic blocker carvedilol restores L-type calcium current in a myocardial infarction model of rabbit. Chin Med J (Engl) 2005;118:377-382.
58. Nessler J, Skrzypek A: The modern view on the role of inflammatory factors in chronic heart failure and possibilities of pharmacological modification (in Polish). Przegl Lek 2003;60:413-417.
59. Escobales N, Crespo MJ: Oxidative-nitrosative stress in hypertension. Curr Vasc Pharmacol 2005;3:231-246.
60. Huang H, Shan J, Pan XH, Wang HP, Qian LB, Xia Q: Carvedilol improved diabetic rat cardiac function depending on antioxidant ability. Diabetes Res Clin Pract 2007;75:7-13.
61. Akbas H, Ozden M, Kanko M, Maral H, Bulbul S, Yavuz S, Ozker E, Berki T: Protective antioxidant effects of carvedilol in a rat model of ischaemia-reperfusion injury. J Int Med Res 2005;33:528-536.
62. Liu N, Yu R, Ruan Y, Zhou Q, Pu J, Li Y: Protective effect of carvedilol on abnormality of L-type calcium current induced by oxygen free radical in cardiomyocytes. J Huazhong Univ Sci Technolog Med Sci 2004;24:433-436.
63. Kawai K, Qin F, Shite J, Mao W, Fukuoka S, Liang CS: Importance of antioxidant and antiapoptotic effects of beta-receptor blockers in heart failure therapy. Am J Physiol Heart Circ Physiol 2004;287:H1003-H1012.
64. Kono Y, Nakamura K, Kimura H, Nishii N, Watanabe A, Banba K, Miura A, Nagase S, Sakuragi S, Kusano KF, Matsubara H, Ohe T: Elevated levels of oxidative DNA damage in serum and myocardium of patients with heart failure. Circ J 2006;70:1001-1005.
65. Nakamura K, Kusano K, Nakamura Y, Kakishita M, Ohta K, Nagase S, Yamamoto M, Miyaji K, Saito H, Morita H, Emori T, Matsubara H, Toyokuni S, Ohe T: Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002;105:2867-2871.